The unlikely duo raising awareness about cancer treatment side effects | Australian Story
ABC News In-depth · 29:282025-07-16
Summary (paraphrased)
This ABC Australian Story episode (July 2025) follows two Australians — Tim, a writer living with metastatic prostate cancer on ten years of androgen deprivation therapy, and Liz, widow of Craig — campaigning for awareness of ADT's devastating side effects. Both describe the same cluster: zero libido, erectile dysfunction, genital shrinkage, breast swelling, emotional blunting, and depression, alongside starkly inadequate informed consent ('I've only had one patient have an adverse reaction'). They frame ADT plainly as the chemical castration of millions of men without support tools, while Tim closes by calling it a 'necessary evil' that saved his life.
Key points by timestamp (paraphrased)
- 00:01:22Framing: ADT 'does save lives but it can also have life wrecking consequences for some patients.'
- 00:10:24ADT explained: therapy to block testosterone 'because prostate cancer actually feeds off testosterone.'
- 00:10:39Informed-consent gap: when Craig's wife asked about mental-health impact, the oncologist said he'd 'only had one patient have an adverse reaction' — so she 'parked it.'
- 00:11:20Craig's onset within ~2 months: irritability, poor sleep, fatigue, visibly rapid aging.
- 00:11:56'Zero libido whatsoever' — described as the key troubling symptom.
- 00:13:31Tim on learning the frontline treatment for the most common cancer in men 'amounted to chemical castration': loss of libido, erectile function, bone density, muscle mass — with no mention of suicide risk in the consent discussion.
- 00:14:24'It absolutely feels like your masculinity is being taken from you... I consider myself entirely asexual' — plus breast swelling, genital shrinkage, and deep emotional vulnerability.
- 00:19:08Convinced ADT caused his darkest periods; calls the warnings 'entirely inadequate' and prescribing ADT without support 'medically negligent.'
- 00:19:50'We're chemically castrating millions of men all the time and not giving them any tools to manage' — the advocacy thesis.
- 00:26:32Balanced close: 'If I hadn't done ADT hormone treatment, I don't think I'd still be here... it was a necessary evil.'
Timestamps come from auto-captions and can be off by about five seconds.
Why it’s in the corpus
Mainstream documentary on prolonged androgen deprivation producing persistent sexual and psychological effects — the clinical real-world parallel to Powers' 'castration trial' concept (DWP-002) and the corpus's androgenic-silencing phenotype. The informed-consent/recognition-gap theme mirrors the PFS/PSSD clinician-dismissal literature (PSSD-008). Useful comparator: androgen-signaling loss with known cause and no expectation of nocebo.
Transcript
This release lists transcript files (qPHfIKwyyj0.srt, qPHfIKwyyj0.txt). They are not bundled with the site yet; drop them into corpus/transcripts/ to publish them.
Related records
- Peer-reviewed paperPSSD Discord pickSIDEfxHUB pick
Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients
Roberto Cosimo Melcangi, Daniele Santi, Roberto Spezzano, Maria Grimoldi, Tommaso Tabacchi, Maria Letizia Fusco, Silvia Diviccaro, Silvia… · The Journal of Steroid Biochemistry and Molecular Biology
Multicenter case-control study of 16 men with post-finasteride syndrome, combining psychiatric/andrological phenotyping with cerebrospinal fluid and plasma neuroactive-steroid measurements in 14 of them (2 declined CSF sampling), compared against 25 surgical…
DISC-0132017PFSPSSD Discord picks - Peer-reviewed paper
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
Reiss AB; Gulkarov S; Pinkhasov A; Sheehan KM; Srivastava A; De Leon J; Katz AE · Medicina
This review surveys how androgen deprivation therapy affects cognition, mood, and quality of life in prostate cancer patients. It reports physiological correlates of ADT including reduced white-matter integrity and impaired hypothalamic function from…
MECH-0272023-12-30Systems review · Oct 2026
